Isospaglumic Acid

Isospaglumic Acid

SCHEMBL288514

CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GNPAT O15228 1/20 0.70
FOLH1 Q04609 8/20 0.56
NAALAD2 Q9Y3Q0 2/20 0.56
RIMKLA Q8IXN7 1/20 0.56
BMP1 P13497 2/20 0.48
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
PTGS2 P35354 1/20 0.47
THPO P40225 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GGH Q92820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isospaglumic Acid SCHEMBL27542882 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL31194414 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL31121839 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL288515 1.00 GNPAT (0.70) GNPATFOLH1NAALAD2RIMKLABMP1
Isospaglumic Acid SCHEMBL6438535 0.98 GNPAT (0.68) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL29517621 0.94 GNPAT (0.63) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL13467302 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL17950968 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL19106177 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1
SCHEMBL2248714 0.93 GNPAT (0.60) GNPATFOLH1NAALAD2RIMKLABMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2385 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737566-A1 CAS12 PROTEIN AND USE THEREOF Reforgene Medicine (CN) 2026-05-06 EP claimed
EP-4692783-A1 BIOMARKER AND SYSTEM FOR PREDICTING EVOLUTION INTO ACLF OR DEATH OF ACLF PATIENT, AND USES THEREOF Shanghai Ganning Medical and Technology Co., Ltd (CN) 2026-02-11 EP claimed
EP-4692338-A1 CAS12 PROTEIN AND USE THEREOF Guangzhou Reforgene Medicine Co., Ltd. (CN) 2026-02-11 EP claimed
WO-2025199636-A1 TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF MCMASTER UNIVERSITY (CA) 2025-10-02 WO claimed
EP-4619763-A1 BIOMARKER PANEL FOR BRAIN SPECIFIC ABNORMAL NEUROLOGICAL CONDITIONS USING BIOFLUID SAMPLES Gryphon Bio, Inc. (US) 2025-09-24 EP claimed
WO-2025061113-A1 CAS12 PROTEIN AND USE THEREOF 广州瑞风生物科技有限公司 2025-03-27 WO claimed
CN-119510604-A Biomarker for predicting whether ACLF patient will die, system and application thereof 上海甘宁医疗科技有限公司 2025-02-25 CN claimed
CN-119470683-A Biomarker for predicting whether ACLF will be formed, system and application thereof 上海甘宁医疗科技有限公司 2025-02-18 CN claimed
CN-119320276-A Ultralow-temperature sintered ceramic material and preparation method and application thereof 肇庆学院 2025-01-17 CN claimed
EP-4475953-A1 NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY SAHIN, Fikret (TR) 2024-12-18 EP claimed
EP-1011327-A1 TREATMENT OR PROPHYLAXIS OF RETINAL PATHOLOGY AND SPINAL CORD INJURY Department of the Army, U.S. Governament U.S. Army Medical & Research and Materiel Command (US) 2000-06-28 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
US-5981209-A Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia GUILFORD PHARMACEUTICALS INC. (US) 1999-11-09 US claimed
WO-1999032887-A1 DETECTION OF PROSTATE DISEASE BY MEASURING NAALADASE ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1999-07-01 WO claimed
WO-1999008521-A1 TREATMENT OR PROPHYLAXIS OF RETINAL PATHOLOGY AND SPINAL CORD INJURY DEPARTMENT OF THE ARMY, U.S. GOVERNMENT (US) 1999-02-25 WO claimed
EP-0660707-A4 METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE. CHILDRENS MEDICAL CENTER (US) 1998-05-13 EP claimed
EP-0660707-A1 METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE The Children's Medical Center Corporation (US) 1995-07-05 EP claimed
WO-1994005275-A9 METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE 1994-04-28 WO claimed
WO-1994005275-A1 METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1994-03-17 WO claimed
WO-1992017168-A1 METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1992-10-15 WO claimed